Contineum Therapeutics (CTNM) Income towards Parent Company (2023 - 2026)

Contineum Therapeutics' Income towards Parent Company history runs 4 years deep, the most recent figure standing at -$56.8 million for Q2 2026.

• In Q2 2026, Income towards Parent Company fell 149.44% year-over-year to -$56.8 million; the TTM figure through Jun 2026 stood at -$147.0 million (down 129.78% YoY), while the FY2025 annual figure was -$107.8 million, down 223.05% from the prior year.
• Income towards Parent Company for Q2 2026 stood at -$56.8 million, down from -$41.5 million in the prior quarter.
• The five-year high for Income towards Parent Company was $41.6 million in Q2 2023, with the low at -$56.8 million in Q2 2026.
• The 4-year median for Income towards Parent Company is -$11.2 million (2023), against an average of -$15.0 million.
• The sharpest annual moves came in 2024 and 2025: Income towards Parent Company jumped 53.46% in 2024, then slumped 219.79% in 2025.
• Contineum Therapeutics' Income towards Parent Company stood at -$12.2 million in 2023, then surged by 53.46% to -$5.7 million in 2024, then plunged by 180.95% to -$16.0 million in 2025, then tumbled by 255.81% to -$56.8 million in 2026.
• Business Quant data shows CTNM's Income towards Parent Company at -$56.8 million in Q2 2026, -$41.5 million in Q1 2026, and -$16.0 million in Q4 2025.